BMO Capital Markets, the investment and corporate banking arm of BMO Financial Group, hired Evan Seigerman as a managing director and senior equity research analyst covering the biotechnology and pharmaceutical industries. Seigerman’s hire is a part of BMO’s strategy to build out its healthcare franchise.
In addition to Seigerman, Trung Huynh joined the BMO healthcare research team to support the firm’s expansion and growth. Huynh has more than 10 years of experience covering therapeutic and pharmaceutical companies, and most recently was with Credit Suisse in London.
Seigerman will be based in New York and report to Bert Powell, global director of equity research for BMO Capital Markets. He will drive the expansion of BMO’s healthcare research franchise, which currently consists of four analysts, including Seigerman and:
- Gary Nachman, who covers biopharma/biotechnology
- Matthew Luchini, who covers biotechnology
- Matt Borsch, CFA, who covers managed care/providers
_x000D_
_x000D_
_x000D_
“Evan brings a deep understanding of the biotech sector across market caps and therapeutic areas,” Powell said. “In addition, he brings a client-centric focus with the vision to build a market-leading research franchise.”
Seigerman has more than a decade of experience, most recently at Credit Suisse in New York, where he covered the U.S. biopharmaceuticals sector. He has worked at Barclays Capital and Deutsche Bank Securities, also in New York, and was selected by Business Insider as a 2021 “Rising Star” of equity research.
